个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共12条记录   Phosphodiesterase inhibitors in inflammatory bowel disease [作者：Salari, P; Abdollahi, M,期刊：Expert opinion on investigational drugs, 页码：261-264 , 文章类型： Editorial Material，,卷期：2012年21-3] Inflammatory bowel disease (IBD) is fundamentally a relapsing and remitting disease appearing in forms of ulcerative colitis (UC) or Crohn's disease (CD) with a non-well-known etiology. With the hope to prevent adverse d... A novel vaginal microbicide containing the rationally designed anti-HIV compound HI-443 (N '-[2-(2-thiophene)ethyl]-N '-[2-(5-bromopyridyl)] thiourea]) [作者：D'Cruz, OJ; Qazi, S; Yiv, S; Uckun, FM,期刊：Expert opinion on investigational drugs, 页码：265-279 , 文章类型： Review，,卷期：2012年21-3] Introduction: A focal point in contemporary research aimed at preventing the heterosexual spread of AIDS has been the development of intravaginal anti-HIV microbicides to curb the mucosal human immunodeficiency virus typ... Novel targeted therapies in head and neck cancer [作者：Ferreira, MBA; Lima, JPSN; Cohen, EEW,期刊：Expert opinion on investigational drugs, 页码：281-295 , 文章类型： Review，,卷期：2012年21-3] Introduction: Molecularly targeted therapy, with the potential for increased selectivity and fewer adverse effects, hold promise in the treatment of HNSCC.Areas covered: Targeted agents for HNSCC expected to improve the ... Current and prospective disease-modifying therapies for amyotrophic lateral sclerosis [作者：Morren, JA; Galvez-Jimenez, N,期刊：Expert opinion on investigational drugs, 页码：297-320 , 文章类型： Review，,卷期：2012年21-3] Introduction: Amyotrophic lateral sclerosis (ALS) is a devastating illness of unclear etiology affecting motor neurons. It causes unremitting muscle paralysis, atrophy and death usually within 3 - 5 years from diagnosis.... The therapeutic potential of GPR119 agonists for type 2 diabetes [作者：Ohishi, T; Yoshida, S,期刊：Expert opinion on investigational drugs, 页码：321-328 , 文章类型： Review，,卷期：2012年21-3] Introduction: Patients with type 2 diabetes mellitus (T2DM) are reaching an explosive number. Pancreatic beta cell dysfunction is the characteristic feature of the progression of T2DM and there is an increasing need for ... A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases [作者：Pandey, S; Srivastava, SK; Ramana, KV,期刊：Expert opinion on investigational drugs, 页码：329-339 , 文章类型： Review，,卷期：2012年21-3] Introduction: Aldose reductase (AR) was initially thought to be involved in the secondary diabetic complications because of its glucose-reducing potential. However, evidence from recent studies indicates that AR is an ex... Development of novel CXCR4-based therapeutics [作者：Peled, A; Wald, O; Burger, J,期刊：Expert opinion on investigational drugs, 页码：341-353 , 文章类型： Review，,卷期：2012年21-3] Introduction: During embryogenesis, CXCR4, a chemokine receptor, and its ligand, stromal cell-derived factor-1 (SDF-1/CXCL12), are critically involved in the development of the hematopoietic, nerve and endothelial tissue... PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies [作者：Winer, ES; Ingham, RR; Castillo, JJ,期刊：Expert opinion on investigational drugs, 页码：355-361 , 文章类型： Review，,卷期：2012年21-3] Introduction: There has been a significant paradigm shift in the manner in which lymphoid malignancies are treated and managed. Treatment has been moving away from conventional chemotherapy and towards targeted therapy. ... Obatoclax mesylate: pharmacology and potential for therapy of hematological neoplasms [作者：Joudeh, J; Claxton, D,期刊：Expert opinion on investigational drugs, 页码：363-373 , 文章类型： Editorial Material，,卷期：2012年21-3] Introduction: Augmentation and acceleration of apoptosis for cancer therapy are logical therapeutic strategies given the increasing body of data suggesting the dysregulation of control of cell death in many neoplasms. Ap... Update on alisporivir in treatment of viral hepatitis C [作者：Flisiak, R; Jaroszewicz, J; Flisiak, I; Lapinski, T,期刊：Expert opinion on investigational drugs, 页码：375-382 , 文章类型： Editorial Material，,卷期：2012年21-3] Introduction: There are two classes of anti-hepatitis C virus (HCV) agents currently in development: direct-acting antivirals (DAA) and host-targeting antivirals (HTA). Cyclophilin inhibitor alisporivir (ALV), previously... Danusertib, an aurora kinase inhibitor [作者：Meulenbeld, HJ; Mathijssen, RHJ; Verweij, J; de Wit, R; de Jonge, MJA,期刊：Expert opinion on investigational drugs, 页码：383-393 , 文章类型： Editorial Material，,卷期：2012年21-3] Introduction: Drugs that interfere with the normal progression of mitosis belong to the most successful cytotoxic agents currently used for anticancer treatment. Aurora kinases are serine/threonine kinases that function ... Elvitegravir: a once-daily inhibitor of HIV-1 integrase [作者：Wills, T; Vega, V,期刊：Expert opinion on investigational drugs, 页码：395-401 , 文章类型： Editorial Material，,卷期：2012年21-3] Introduction: Elvitegravir (EVG) is a potent inhibitor of HIV-1 integrase (IN) undergoing Phase III clinical trials. It blocks the strand-transfer step in a multi-step process that allows double-stranded cDNA to be irrev...